Internal Medicine, Nephrology · Belleville, NJ
NPI
1588767875
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
140 Belmont Ave, Ste 103
Belleville, NJ, 07109
Phone (973) 751-7870
Groups this clinician bills Medicare through
Medicare paid, 2024
$133K
790 services
Medicare patients, 2024
157
Average age 71
Drug cost, 2024
$507K
1,889 prescriptions
Company payments, 2025
$313
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Gayithri R Keshav was code 90960 (esrd related services (not dialysis)), 256 times for 46 patients. In total Gayithri R Keshav billed 790 services in 17 codes, and Medicare paid $133K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-02-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 90960 ESRD Related Services (not dialysis) | Office | 256 | 46 | $280.09 | $72K |
| 99214 Office E&M - Established | Office | 216 | 79 | $103.11 | $22K |
| 90961 ESRD Related Services (not dialysis) | Office | 98 | 43 | $224.92 | $22K |
| 36415 Venipuncture Blood Collection | Office | 47 | 29 | $8.65 | $407 |
| 99233 Hospital E&M - Subsequent | Facility | 36 | 23 | $96.61 | $3,478 |
| 90935 Hemodialysis | Facility | 35 | 13 | $57.56 | $2,015 |
| 99232 Hospital E&M - Subsequent | Facility | 33 | 21 | $64.23 | $2,120 |
| 90962 ESRD Related Services (not dialysis) | Office | 23 | 14 | $164.14 | $3,775 |
| 99222 Hospital E&M - Initial | Facility | 16 | 15 | $106.50 | $1,704 |
| 99204 Office E&M - New | Office | 15 | 15 | $142.23 | $2,133 |
By year: 2022 $234K for 2,066 services; 2023 $228K for 1,932 services; 2024 $133K for 790 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 47 | 29 | $8.65 | $407 |
Medicare prescription drug claims, 2024
In 2024, the drug Gayithri R Keshav prescribed most often to Medicare patients was Levocarnitine, with 418 prescriptions and refills. In total Gayithri R Keshav wrote 1,889 Medicare prescriptions that cost $507K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levocarnitine Generic | 418 | 881 | 161 | $53K |
| Farxiga Dapagliflozin Propanediol | 163 | 321 | 56 | $179K |
| Sevelamer Carbonate Generic | 97 | 173 | 33 | $19K |
| Furosemide Generic | 63 | 126 | 26 | $325 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 54 | 54 | 11 | $1,020 |
| Amlodipine Besylate Generic | 52 | 134 | 23 | $580 |
| Metoprolol Tartrate Generic | 43 | 99 | 13 | $239 |
| Lokelma Sodium Zirconium Cyclosilicate | 39 | 54 | 19 | $42K |
| Allopurinol Generic | 38 | 76 | 11 | $128 |
| Velphoro Sucroferric Oxyhydroxide | 33 | 37 | Under 11 | $74K |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 33 | 69 | 13 | $319 |
| Tramadol Hcl Generic | 31 | 31 | 12 | $83.72 |
| Gabapentin Generic | 27 | 29 | Under 11 | $135 |
| Mupirocin Generic | 27 | 30 | Under 11 | $521 |
| Atorvastatin Calcium Generic | 23 | 67 | Under 11 | $297 |
Brand drugs: - claims; generic drugs: 1,502 claims; opioid claims: 32.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Gayithri R Keshav $313 ($313 in general payments such as food, travel and fees) from 8 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $105.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 6 | $105 |
| Vifor Pharma, Inc. | 4 | $64.29 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $35.11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $34.9 |
| Travere Therapeutics, Inc. TVTX | 2 | $19.88 |
| ANI Pharmaceuticals, Inc. ANIP | 1 | $19.63 |
| Mallinckrodt Hospital Products Inc. | 1 | $17.9 |
| Calliditas Therapeutics US Inc. | 1 | $15.78 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.